Eli Lilly and Company and Takeda Pharmaceutical Company Limited: A Detailed Gross Profit Analysis

Eli Lilly vs. Takeda: A Decade of Profit Growth

__timestampEli Lilly and CompanyTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014146831000001256834000000
Thursday, January 1, 2015149215000001271973000000
Friday, January 1, 2016155672000001173296000000
Sunday, January 1, 2017168011000001274610000000
Monday, January 1, 2018168116000001437534000000
Tuesday, January 1, 2019175983000002201424000000
Wednesday, January 1, 2020190565000002203504000000
Friday, January 1, 2021210056000002462160000000
Saturday, January 1, 2022219116000002783406000000
Sunday, January 1, 2023270419000002832257000000
Monday, January 1, 2024366244000012832257000000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Eli Lilly and Takeda

In the ever-evolving landscape of the pharmaceutical industry, Eli Lilly and Company and Takeda Pharmaceutical Company Limited stand as titans. Over the past decade, these companies have demonstrated remarkable growth in gross profit, reflecting their strategic prowess and market adaptability. From 2014 to 2023, Eli Lilly's gross profit surged by approximately 84%, showcasing its robust pipeline and successful product launches. Meanwhile, Takeda's gross profit exhibited a steady climb, with a notable 125% increase, driven by strategic acquisitions and a strong global presence.

Key Insights

  • Eli Lilly: Witnessed a consistent upward trend, peaking in 2023 with a gross profit of $27 billion.
  • Takeda: Achieved a significant milestone in 2023, reaching a gross profit of $2.83 trillion.

While Eli Lilly's data for 2024 remains elusive, Takeda continues to maintain its impressive figures, hinting at sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025